Clinical TrialJun 11, 2026, 07:31 AM
Immuneering Doses First Patient in Pivotal Phase 3 Pancreatic Cancer Trial
AI Summary
Immuneering Corporation announced the dosing of the first patient in MAPKeeper 301, a global, randomized, open-label pivotal Phase 3 clinical trial. This trial evaluates atebimetinib plus modified gemcitabine/nab-paclitaxel (mGnP) in first-line metastatic pancreatic cancer patients, a challenging malignancy with an urgent need for new treatment options. Atebimetinib is a novel MEK inhibitor designed to improve survival and tolerability. Topline data, including the primary endpoint of overall survival, is expected in mid-2028.
Key Highlights
- First patient dosed in MAPKeeper 301, a global pivotal Phase 3 trial for atebimetinib.
- Trial evaluates atebimetinib + modified gemcitabine/nab-paclitaxel (mGnP) in first-line metastatic pancreatic cancer.
- Primary endpoint is overall survival (OS); key secondary endpoints include PFS, ORR, DCR.
- Topline data readout, including primary endpoint of OS, anticipated in mid-2028.
- Atebimetinib is a novel MEK inhibitor designed to target RAS, RAF, and MAPK pathway-driven cancers.
- Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis with approximately 13% five-year survival rate.
- The global MAPKeeper 301 trial identifier is NCT07562152.
Price Impact
More from IMRX